Stocks · News reference

Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18

Aug 10, 2026, 12:13 PMBenzinga Newsdesk

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 10, 2026, 11:33 AMBenzinga Newsdesk
CervoMed To Present Neflamapimod, Oral, Small Molecule, Drug Candidate Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, At ISFTD Annual Meeting
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual MeetingnfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology,
CRVO
BenzingaAug 12, 2026, 11:25 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
CRVO
SEC EDGARAug 10, 2026, 8:07 PMSEC EDGAR
8-K filing — CervoMed Inc. (CRVO)
Filed: 2026-08-10 AccNo: 0001437749-26-026771 Size: 207 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
CRVO